Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label multicenter study of CN201 (MK-1045) in precursor B-cell acute lymphoblastic leukemia
CTR20222129Phase 2Active
- Sponsor
- Antengene
- Start
- Nov 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CN201 in acute lymphoblastic leukemia (ALL), sponsored by Antengene. Started Nov 2022; status: active.
02
Drugs
CN201
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on CTR20222129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222129.